Vaxcyte (PCVX) to Release Quarterly Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is expected to be announcing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.46) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $54.10 on Tuesday. The firm’s fifty day moving average price is $49.09 and its two-hundred day moving average price is $42.37. The stock has a market cap of $7.08 billion, a PE ratio of -11.18 and a beta of 1.33. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $85.57.

Insider Buying and Selling

In other Vaxcyte news, SVP Elvia Cowan sold 11,623 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16. Following the completion of the transaction, the senior vice president owned 14,534 shares in the company, valued at approximately $696,469.28. This trade represents a 44.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the transaction, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This trade represents a 28.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Vaxcyte

Hedge funds have recently bought and sold shares of the company. Empowered Funds LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $211,000. CIBC Asset Management Inc acquired a new position in shares of Vaxcyte during the 4th quarter valued at $208,000. Mariner LLC bought a new position in Vaxcyte during the third quarter worth $279,000. Quantbot Technologies LP acquired a new stake in Vaxcyte in the second quarter worth $222,000. Finally, Cetera Investment Advisers grew its holdings in Vaxcyte by 13.8% in the second quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares during the period. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PCVX. Needham & Company LLC upped their target price on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a research report on Monday, November 10th. Finally, Guggenheim restated a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.